| |
|
|
|
Oxford Global, Copthorne Tara Hotel, London
15 - 16 May 2017
Oxford Global are proud to present the 2nd Annual Advances in Immuno-Oncology Congress, taking place 15-16 May 2017 in London UK. The event features 200 delegates from world renowned academic institutions, hospitals, global pharmaceutical organisations and leading biotechnology companies. 36 presentations and case studies will focus on the key developments in Immuno-Oncology with specific reference to the discovery of therapeutic areas, pre-clinical and clinical studies, screening, assays and modelling The congress has 4 interactive streams: - Discovery of Immuno-Oncology Therapies
- Pre-clinical Immuno-Oncology
- Screening, Assays and Modelling in Immuno-Oncology
- Immuno-Oncology: Therapeutic Approaches, Clinical Research and Clinical Trials
14 pre-scheduled one to one meetings, exhibition and informal networking opportunities
|
|
|
|
|
|
|
|
Organized by:
|
|
Oxford Global |
|
|
Invited Speakers:
|
|
2017 Speakers Include: - Philip Arlen, President and CEO, Precision Biologics, Inc.
- Jakob Dupont, Senior Vice President & Chief Medical Officer, OncoMed Pharmaceuticals
- Anne Altmeyer, Vice President, Business Development, Negotiations, Baxalta
- Graham Pockley, CEO Multimmune GmbH
- Ulf Grawunder, CEO, NBE Therapeutics
- Jonathan Zalevsky, Vice President, Biology & Preclinical Development, Nektar Therapeutics
- Gavin Thurston/Regeneron rep, Vice President, Oncology and Angiogenesis Research, Regeneron Pharmaceuticals
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
N/A
|
|
|
|
|
|
|
|
Registration:
|
|
For further information about registration, please contact Danielle Dalby at d.dalby@oxfordglobal.co.uk or call +44 (0)1865 248455
|
|
|
|
|
|
|
|
|